Over the last decade, successful partnerships, from pre-clinical through commercial, have been one of the main contributors to our position as specialists in brain diseases and experts in neuroscience research. The importance of partnerships is recognised throughout the organisation, and we strive continuously to be the partner of choice.
Why partner with Lundbeck?
1. Fully integrated company
Lundbeck is a fully integrated company with more approximately 6000 employees in 57 countries; we have core competencies in research, clinical development, production, marketing and sales. Partnered products have been successfully integrated into our value chain – from pre-clinical to marketed products.
2. Proven track record of developing products for the market
The majority of Lundbeck’s currently marketed products are based on successful internal innovations and external development opportunities. As a result, we have a strong late-stage pipeline with five products in phase III/pre-registration, which we expect to launch within the next few years.
The success of our pipeline is due to our 1,200 dedicated research and development (R&D) staff, who are skilled in development and focused on project teams. In 2013, we invested approximately 20% of our total revenue in R&D.
3. Proven track record of commercial success
Thanks to Lundbeck’s strong platform and presence in over 100 countries, we have created commercial successes for our products. Our anti-depressant Cipralex/Lexapro is a market leader in 43 countries. Moreover, in various markets worldwide we market pharmaceuticals for the treatment of alcohol dependence, Alzheimer’s disease, epilepsy, Huntington’s disease, insomnia, Parkinson’s disease, schizophrenia and bipolar disorder.
This success is built on a large global infrastructure for sales and marketing, with almost 3,000 employees and strong regional commercial capabilities. Our committed commercial organisation is dedicated to bringing therapies to the patients that need them.
4. Dedicated to brain diseases
Building on our own innovations and external licensing agreements, Lundbeck has more than 50 years’ experience within brain diseases. Our R&D and commercial teams are dedicated to brain diseases, and we have a strong network among key opinion leaders and specialists in psychiatry and neurology as well as among GPs.
Our strategy is to strengthen our position as a leading company within brain diseases. Brain diseases are among the greatest global burdens of disease: the patient population is expected to increase over the coming years and the unmet medical need in this area is substantial.
5. Flexible and fast decision-making on partnerships
Lundbeck’s top management is committed to developing partnerships and has designed a process to ensure structured and fast decision making when evaluating new partnering opportunities.
Our financial position is solid, with a strong balance sheet and cash generation, enabling continuous investment in external opportunities.